Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,813.00 GBX | -1.55% |
|
+2.86% | +32.40% |
02:28pm | Juul Labs Wins FDA Clearance to Keep E-Cigarettes on US Market | MT |
01:11pm | FDA approves Juul's tobacco and menthol e-cigarettes | RE |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.96 | 5 | 5.01 | 5.8 | 5.15 | |||||
Return on Total Capital | 6.39 | 6.43 | 6.45 | 7.45 | 6.81 | |||||
Return On Equity % | 10.33 | 10.7 | 9.57 | -22.06 | 6.18 | |||||
Return on Common Equity | 10.11 | 10.47 | 9.29 | -22.53 | 5.92 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 83.95 | 82.1 | 82.63 | 82.07 | 82.33 | |||||
SG&A Margin | 10.29 | 14.83 | 13.85 | 14.13 | 15.27 | |||||
EBITDA Margin % | 47.17 | 46.48 | 44.05 | 48.66 | 45.7 | |||||
EBITA Margin % | 44.26 | 42.83 | 42.13 | 47.2 | 44.26 | |||||
EBIT Margin % | 42.94 | 42.83 | 42.13 | 46.33 | 37.87 | |||||
Income From Continuing Operations Margin % | 25.47 | 27.15 | 24.76 | -52.01 | 12.3 | |||||
Net Income Margin % | 24.83 | 26.48 | 24.1 | -52.66 | 11.86 | |||||
Net Avail. For Common Margin % | 24.83 | 26.43 | 23.93 | -52.82 | 11.7 | |||||
Normalized Net Income Margin | 23.06 | 23.54 | 22.76 | 25.45 | 23.88 | |||||
Levered Free Cash Flow Margin | 25.96 | 25.74 | 24.06 | 27.17 | 39.73 | |||||
Unlevered Free Cash Flow Margin | 30.35 | 29.4 | 27.81 | 31.36 | 44.02 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.18 | 0.19 | 0.19 | 0.2 | 0.22 | |||||
Fixed Assets Turnover | 4.87 | 5.13 | 5.63 | 5.77 | 5.77 | |||||
Receivables Turnover (Average Receivables) | 6.6 | 8.92 | 9.86 | 9.93 | 9.01 | |||||
Inventory Turnover (Average Inventory) | 0.68 | 0.82 | 0.88 | 0.92 | 0.96 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.88 | 0.85 | 0.86 | 0.91 | 0.76 | |||||
Quick Ratio | 0.46 | 0.48 | 0.48 | 0.58 | 0.51 | |||||
Operating Cash Flow to Current Liabilities | 0.63 | 0.64 | 0.58 | 0.68 | 0.54 | |||||
Days Sales Outstanding (Average Receivables) | 55.48 | 40.94 | 37 | 36.76 | 40.62 | |||||
Days Outstanding Inventory (Average Inventory) | 534.76 | 447.69 | 415.98 | 395.86 | 382.58 | |||||
Average Days Payable Outstanding | 879.23 | 359.78 | 280.21 | 156.65 | 147.16 | |||||
Cash Conversion Cycle (Average Days) | -289 | 128.85 | 172.77 | 275.97 | 276.04 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 69.84 | 58.84 | 56.98 | 75.41 | 73.91 | |||||
Total Debt / Total Capital | 41.12 | 37.04 | 36.3 | 42.99 | 42.5 | |||||
LT Debt/Equity | 63.42 | 52.92 | 51.15 | 67.24 | 65.28 | |||||
Long-Term Debt / Total Capital | 37.34 | 33.31 | 32.58 | 38.33 | 37.54 | |||||
Total Liabilities / Total Assets | 54.28 | 50.93 | 50.69 | 55.41 | 57.95 | |||||
EBIT / Interest Expense | 6.11 | 7.31 | 7.02 | 6.91 | 5.53 | |||||
EBITDA / Interest Expense | 6.71 | 7.94 | 7.34 | 7.31 | 6.72 | |||||
(EBITDA - Capex) / Interest Expense | 6.43 | 7.59 | 7.02 | 7.05 | 6.45 | |||||
Total Debt / EBITDA | 3.62 | 3.32 | 3.54 | 2.99 | 3.1 | |||||
Net Debt / EBITDA | 3.34 | 3.05 | 3.21 | 2.59 | 2.61 | |||||
Total Debt / (EBITDA - Capex) | 3.77 | 3.48 | 3.7 | 3.09 | 3.23 | |||||
Net Debt / (EBITDA - Capex) | 3.48 | 3.19 | 3.35 | 2.68 | 2.73 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -0.39 | -0.36 | 7.67 | -1.35 | -5.19 | |||||
Gross Profit, 1 Yr. Growth % | 0.92 | -1.13 | 8.37 | -2.01 | -4.89 | |||||
EBITDA, 1 Yr. Growth % | 6 | -0.79 | 1.63 | 7.26 | -10.23 | |||||
EBITA, 1 Yr. Growth % | 6.65 | -0.43 | 6.33 | 7.67 | -10.37 | |||||
EBIT, 1 Yr. Growth % | 8.35 | -0.43 | 6.33 | 8.49 | -21.85 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 12.22 | 6.25 | -1.84 | -307.26 | -122.42 | |||||
Net Income, 1 Yr. Growth % | 12.2 | 6.27 | -1.99 | -315.53 | -121.35 | |||||
Normalized Net Income, 1 Yr. Growth % | 6.19 | 1.65 | 4.56 | 9.95 | -10.2 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 12.01 | 5.99 | -1.25 | -321.51 | -121.03 | |||||
Accounts Receivable, 1 Yr. Growth % | -9.09 | 8.51 | -12.98 | 10.66 | -1.11 | |||||
Inventory, 1 Yr. Growth % | -1.58 | -11.99 | 7.43 | -12.93 | -6.52 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -8.3 | -2.11 | -1.74 | -5.84 | -4.45 | |||||
Total Assets, 1 Yr. Growth % | -2.35 | -0.24 | 11.78 | -22.68 | 0.15 | |||||
Tangible Book Value, 1 Yr. Growth % | -4.04 | -8.03 | 10.68 | -19.94 | 3.81 | |||||
Common Equity, 1 Yr. Growth % | -1.92 | 7.22 | 12.32 | -30.25 | -5.56 | |||||
Cash From Operations, 1 Yr. Growth % | 8.78 | -0.71 | 6.97 | 3.08 | -5.5 | |||||
Capital Expenditures, 1 Yr. Growth % | -23.04 | 3.13 | -0.76 | -12.05 | 5.65 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 60.92 | -0.81 | -0.63 | 5.8 | 38.51 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 49.52 | -3.16 | 0.99 | 6.64 | 32.94 | |||||
Dividend Per Share, 1 Yr. Growth % | 3.65 | 2.47 | 1.02 | 2 | 2 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 2.59 | -0.37 | 3.58 | 3.07 | -3.29 | |||||
Gross Profit, 2 Yr. CAGR % | 4.17 | -0.77 | 3.51 | 3.05 | -3.93 | |||||
EBITDA, 2 Yr. CAGR % | 5.95 | 2.3 | 0.62 | 6.03 | -2.54 | |||||
EBITA, 2 Yr. CAGR % | 6.64 | 2.78 | 2.7 | 7.03 | -1.58 | |||||
EBIT, 2 Yr. CAGR % | 5.04 | 2.78 | 2.7 | 7.65 | -7.71 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 2.81 | 9.19 | 2.13 | 42.64 | -31.83 | |||||
Net Income, 2 Yr. CAGR % | 3.01 | 9.19 | 2.06 | 45.34 | -32.16 | |||||
Normalized Net Income, 2 Yr. CAGR % | 4.09 | 2.94 | 2.87 | 7.67 | -0.37 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 2.94 | 8.96 | 2.3 | 47.9 | -31.74 | |||||
Accounts Receivable, 2 Yr. CAGR % | 13.9 | -5.67 | -2.83 | -1.87 | 4.61 | |||||
Inventory, 2 Yr. CAGR % | -0.26 | -6.93 | -2.76 | -3.28 | -9.78 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -1.03 | -5.26 | -1.93 | -3.81 | -5.15 | |||||
Total Assets, 2 Yr. CAGR % | -3 | -1.3 | 5.6 | -7.04 | -12 | |||||
Tangible Book Value, 2 Yr. CAGR % | -5.24 | -6.05 | 0.89 | -5.87 | -8.84 | |||||
Common Equity, 2 Yr. CAGR % | -2.07 | 2.54 | 9.74 | -11.49 | -18.84 | |||||
Cash From Operations, 2 Yr. CAGR % | -2.5 | 3.93 | 3.06 | 5 | -1.3 | |||||
Capital Expenditures, 2 Yr. CAGR % | -17.89 | -10.91 | 1.17 | -6.57 | -3.6 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -7.98 | 27.02 | -0.08 | 6.08 | 20.14 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -6.28 | 20.33 | -0.67 | 6.77 | 18.28 | |||||
Dividend Per Share, 2 Yr. CAGR % | 3.82 | 3.06 | 1.74 | 4.52 | 5.03 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 9.63 | 1.6 | 2.24 | 1.91 | 0.24 | |||||
Gross Profit, 3 Yr. CAGR % | 14.19 | 1.96 | 2.19 | 1.63 | 0.33 | |||||
EBITDA, 3 Yr. CAGR % | 15.5 | 3.29 | 2.22 | 3.7 | 0.04 | |||||
EBITA, 3 Yr. CAGR % | 16.75 | 3.12 | 3.82 | 4.44 | 0.61 | |||||
EBIT, 3 Yr. CAGR % | 15.58 | 3.12 | 3.82 | 4.93 | -3.52 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -44.14 | 3.94 | 5.39 | 29.3 | -23.02 | |||||
Net Income, 3 Yr. CAGR % | -44.52 | 4.08 | 5.33 | 30.94 | -23.31 | |||||
Normalized Net Income, 3 Yr. CAGR % | -31.97 | 3.3 | 3.32 | 5.68 | 1.03 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -46.56 | 3.95 | 5.44 | 32.35 | -22.8 | |||||
Accounts Receivable, 3 Yr. CAGR % | 4.02 | 1.49 | -8.17 | 1.47 | -1.62 | |||||
Inventory, 3 Yr. CAGR % | 0.76 | -4.33 | -2.37 | -6.28 | -4.38 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 1.2 | -1.39 | -4.1 | -3.25 | -4.02 | |||||
Total Assets, 3 Yr. CAGR % | -0.8 | -2.09 | 2.88 | -4.82 | -4.7 | |||||
Tangible Book Value, 3 Yr. CAGR % | -2.67 | -6.13 | -0.77 | -6.59 | -2.75 | |||||
Common Equity, 3 Yr. CAGR % | 1.09 | 0.88 | 5.7 | -5.65 | -9.56 | |||||
Cash From Operations, 3 Yr. CAGR % | 22.32 | -1.91 | 4.93 | 3.07 | 1.38 | |||||
Capital Expenditures, 3 Yr. CAGR % | -13.55 | -11.41 | -7.65 | -3.44 | -2.66 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 13.98 | -5.71 | 17.55 | 3.81 | 15.99 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 14.54 | -5.36 | 13.84 | 3.38 | 14.9 | |||||
Dividend Per Share, 3 Yr. CAGR % | 28.1 | 3.37 | 2.37 | 3.83 | 3.67 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 15.51 | 12.69 | 7.17 | 2.18 | -0.01 | |||||
Gross Profit, 5 Yr. CAGR % | 17.89 | 15.19 | 9.48 | 2.39 | -0.11 | |||||
EBITDA, 5 Yr. CAGR % | 17.91 | 15.73 | 9.07 | 4.15 | 0.72 | |||||
EBITA, 5 Yr. CAGR % | 17.94 | 15.27 | 10.2 | 5.12 | 1.91 | |||||
EBIT, 5 Yr. CAGR % | 17.54 | 15.92 | 10.2 | 4.73 | -1.21 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 7.74 | 7.58 | -28.89 | 17.97 | -11.47 | |||||
Net Income, 5 Yr. CAGR % | 8.33 | 7.91 | -29.21 | 18.95 | -11.66 | |||||
Normalized Net Income, 5 Yr. CAGR % | 12.14 | 7.73 | -19.72 | 4.83 | 1.59 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 3.9 | 3.47 | -30.71 | 19.69 | -11.39 | |||||
Accounts Receivable, 5 Yr. CAGR % | 9.58 | 2.15 | -4.63 | 0.13 | -3.26 | |||||
Inventory, 5 Yr. CAGR % | 7.15 | -1.84 | -0.67 | -3.91 | -5.4 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 10.87 | 6.23 | -0.06 | -2.37 | -4.52 | |||||
Total Assets, 5 Yr. CAGR % | 34.3 | 28.13 | 1.71 | -4.1 | -3.35 | |||||
Tangible Book Value, 5 Yr. CAGR % | 56.38 | 64.53 | -1.22 | -6.02 | -4.08 | |||||
Common Equity, 5 Yr. CAGR % | 67.15 | 52.66 | 4.43 | -4.26 | -4.9 | |||||
Cash From Operations, 5 Yr. CAGR % | 15.7 | 16.08 | 14.22 | 0.8 | 2.39 | |||||
Capital Expenditures, 5 Yr. CAGR % | 1.13 | -2.1 | -7.94 | -9.51 | -6.05 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 22.57 | 20.13 | 8.05 | -1.23 | 20.2 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 23.02 | 19.91 | 8.12 | -0.8 | 16.91 | |||||
Dividend Per Share, 5 Yr. CAGR % | 6.44 | 4.94 | 16.82 | 3.83 | 3.43 |
- Stock Market
- Equities
- BATS Stock
- Financials British American Tobacco p.l.c.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions